Rapid Clotting Technology

The US Army seeks a commercial and/or cooperative development partner for a rapid clotting technology for use in a variety of emergency and surgical situations. The Technology: The US Army has patented the combination of recombinant factor VIIa and fibrinogen for stemming blood loss and restoring hemostasis. This combination is administered intravenously and circulates safely through the body to the site of injury. The approach would be especially useful for treating multiple wounds and internal bleeding. Background: Hemorrhage is one of the most common causes of death among those who die prior to reaching an emergency room or expire in the operating room. Research has demonstrated the individual effectiveness of recombinant factor VIIa and fibrinogen in clotting. Factor VIIa plays a key role in activating the blood coagulation process and fibrinogen provides the raw materials needed to make an effective clot. The combination of factor VIIa and fibrinogen is a logical approach to treating emergency and surgical bleeding. Benefits: Portable: Can be used to treat trauma in the field or en route to a hospital Shelf Stable: Components can be stored for years in dry form or months wet Easy to Use: Reconstitutes quickly and is administered via IV Useful in Difficult Cases: Able to help control bleeding in hard-to-reach injuries, such as pelvic venous plexus tears and deep liver injuries Opportunities: Patent No. 6,825,323 is available for licensing. Further joint development with the Army Institute of Surgical Research is possible under a Cooperative Research and Development Agreement (CRADA). Additional details of the technology, an overview of the licensing process, and an interview with the inventor, are available through TechLink.